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Abstract 
Background: Cobalamin (cbl)‑related remethylation disorders are a heterogeneous group of inherited disorders 
comprising the remethylation of homocysteine to methionine and affecting multiple organ systems, most promi‑
nently the nervous system and the bone marrow. To date, the parenteral, generally intramuscular, lifelong administra‑
tion of hydroxycobalamin (OHCbl) is the mainstay of therapy in these disorders. The dosage and frequency of OHCbl 
is titrated in each patient to the minimum effective dose in order to account for the painful injections. This may result 
in undertreatment, a possible risk factor for disease progression and disease‑related complications.
Results: We describe parenteral administration of OHCbl using a subcutaneous catheter together with a portable 
infusion pump in a home therapy setting in four pediatric patients with remethylation disorders, two patients with 
cblC, one patient with cblG, and one patient with cblE deficiency, in whom intramuscular injections were not or 
no longer feasible. The placement of the subcutaneous catheters and handling of the infusion pump were readily 
accomplished and well accepted by the patients and their families. No adverse events occurred. The use of a small, 
portable syringe driver pump allowed for a most flexible administration of OHCbl in everyday life. The concentrations 
of total homocysteine levels were determined at regular patient visits and remained within the therapeutic target 
range. This approach allowed for the continuation of OHCbl therapy or the adjustment of therapy required to improve 
metabolic control in our patients.
Conclusions: Subcutaneous infusion using a subcutaneous catheter system and a portable pump for OHCbl admin‑
istration in combined and isolated remethylation disorders is safe, acceptable, and effective. It decreases disease 
burden in preventing frequent single injections and providing patient independence. Thus, it may promote long‑term 
adherence to therapy in patients and parents.
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Background
Cobalamin (cbl)-related remethylation disorders com-
prise a heterogeneous group of inherited disorders affect-
ing the remethylation of homocysteine to methionine. 
In different ways, they all lead to a deficient activity of 
methionine synthase: decreased function of the enzyme 
protein itself (cblG; OMIM #250940), decreased function 
of the reactivating enzyme methionine synthase reduc-
tase (cblE; OMIM #236270), or impaired supply of the 
cofactor methylcobalamin (cblC; OMIM #277400, cblD; 
OMIM #277410, cblF; OMIM #277380, cblJ; OMIM 
#614857) [1, 2]. Markedly elevated concentrations of 
total homocysteine (tHcy) in blood are the biochemical 
hallmark of cobalamin-related remethylation disorders. 
Some disorders of intracellular cobalamin metabolism 
(cblC, cblD-MMA/Hcy, cblF, and cblJ) do not only com-
promise the synthesis of methylcobalamin, but also the 
synthesis of adenosylcobalamin, cofactor of the enzyme 
methylmalonyl-CoA mutase, leading to elevated concen-
trations of both tHcy and methylmalonic acid (MMA). 
These disorders are referred to as combined remethyla-
tion disorders [2, 3].
The clinical signs and symptoms of cobalamin-related 
remethylation disorders may vary considerably and affect 
multiple organ systems, most prominently the nervous 
system and the bone marrow. They include megaloblas-
tic anemia, lethargy, failure to thrive, microcephaly, brain 
abnormalities, developmental delay, intellectual deficit, 
seizures, and retinopathy. Most patients present during 
the neonatal period or in early infancy. However, juvenile 
or adult onset manifestations characterized mainly by 
ataxia, dementia, and psychosis have been described [2, 
4].
The treatment of cobalamin-related remethylation dis-
orders aims to reduce tHcy and—in combined defects—
to normalize MMA in order to improve clinical features 
[2]. To achieve this, the administration of hydroxyco-
balamin (OHCbl) is the mainstay of therapy [2] with the 
parenteral route being strongly recommended [5–8]. 
The long-term intravenous (IV) application of OHCbl 
is impracticable for the patients. Hence, cobalamin-
related remethylation disorders are usually treated by 
intramuscular (IM) injections at an individually titrated, 
minimum effective dose. The required frequency of injec-
tions ranges between daily and weekly [2]. However, the 
frequent and painful IM injections present a great bur-
den for patients and their families, and subcutaneous 
(SQ) OHCbl administration has been suggested as an 
alternative parenteral route [9]. Its efficacy, though, is still 
debated [2, 4, 10, 11].
Within the last years, SQ infusion of an increasing 
number of drugs has been described to have favorable 
outcomes with regards to effectiveness, safety, acceptabil-
ity, and efficiency in the pediatric and adult population 
[12].
We implemented the SQ infusion of OHCbl using a SQ 
catheter system together with a small, portable pump in 
four patients with cobalamin-related remethylation dis-
orders in whom frequent IM injections were not or no 
longer feasible. We wish to raise awareness for this easy 
to use access and route of administration.
Results
Patient 1
Patient 1, a girl, was born at 39 + 2  weeks of gestation 
(birth weight 2310  g). She is the first child (G1P1) of 
healthy, non-consanguineous parents of Caucasian ori-
gin. Postnatal adaptation was uneventful. Dried blood 
spots for newborn screening were collected at 35  h of 
age and revealed slightly elevated concentrations of 
propionylcarnitine (8.9  µmol/l; cut-off < 5.9) and MMA 
(59.5  µmol/l; cut-off < 5), whereas the concentration of 
methionine (7  µmol/l; cut-off > 8) was decreased, and 
3-hydroxy-propionic acid (26.7  µmol/l; cut-off < 30) was 
normal. The patient was transferred to our metabolic 
center. Clinical examination revealed feeding problems 
and muscular hypotonia. Confirmation testing at day 
5 demonstrated markedly elevated concentrations of 
MMA (139,500  nmol/l; reference range 73–271), tHcy 
(198 µmol/l; reference range < 12), and propionylcarnitine 
(13.7 µmol/l; reference range < 1.4) in plasma. Analysis of 
organic acids in urine revealed increased excretions of 
MMA (2576 mmol/mol creatinine; reference range < 3.7), 
3-hydroxy-propionat, and methylcitrate. The concen-
trations of ammonia (82  µmol/l; reference range < 110), 
lactate (1.7  mmol/l; reference range < 2.1), vitamin B12 
(1780  pg/ml; reference range 197–771), and folic acid 
(19.8  ng/ml; reference range 3.9–26.8) were unremark-
able. These findings are highly indicative for an inborn 
error of cobalamin metabolism, and supplementation of 
OHCbl 1  mg IV, folic acid 20  mg PO, betaine 250  mg/
kg PO, and initially methionine 25 mg PO per day were 
started. With this treatment, tHcy and MMA in plasma 
declined to tHcy 47 µmol/l and MMA 12,360 nmol/l on 
day 10 of life (Fig.  1a). The diagnosis of cblC deficiency 
was confirmed by sequence analysis of the MMACHC 
Keywords: Remethylation disorder, Cobalamin, Hydroxycobalamin, Subcutaneous catheter system, Subcutaneous 
infusion, Infusion pump
Page 3 of 8Lotz‑Havla et al. Orphanet J Rare Dis          (2021) 16:215  
gene. Two variants, the canonical splice site variant 
c.81 + 1G > T, p.? and a deletion of exon 4, were iden-
tified in compound heterozygous state. Both variants 
had not previously been described and were classified 
as pathogenic according to the American College of 
Medical Genetics (ACMG) guidelines [13]. The vari-
ant c.81 + 1G > T is predicted to disrupt the splice donor 
site of exon 1 as demonstrated for the known pathogenic 
variant c.81 + 1G > A [14]. The deletion of exon 4 is pre-
dicted to result in a functional loss of the enzyme.
Within the following weeks, treatment was adjusted 
based on tHcy concentrations in plasma (Fig.  1a). 
Treatment with methionine was stopped, betaine was 
continued with 250 mg/kg PO and folic acid with 10 mg 
PO per day. OHCbl was changed from IV to IM admin-
istration at day 8 of life. To achieve tHcy concentrations 
as low as possible (< 40  µmol/l), the administration of 
OHCbl (1  mg) was required every other day. The IM 
injections were painful for the newborn and went along 
with an enormous psychological stress for the mother. 
The mother was inclined to refuse further IM therapy. 
To reduce the burden of frequent injections, we started 
the SQ administration of OHCbl using a SQ cath-
eter and a portable syringe driver pump as described 
in the methods section. The placement of the small 
SQ catheter was well tolerated and could be executed 
by the parents allowing for home therapy. The slow, 
pump-controlled delivery of OHCbl over 1 h prevented 
the pain induced by the swift delivery of the medica-
tion in IM or SQ injections. No complications such 
as local infections at the catheter site occurred. The 
use of a portable infusion pump of small dimensions 
and low weight allowed for a most flexible administra-
tion of OHCbl in everyday life. Treatment was started 
with OHCbl 1  mg three times a week and increased 
to daily administration, resulting in tHcy concentra-
tions in plasma within the target range (< 60 µmol/l [2]) 
(Fig. 1a).
Patient 1 is now 3  years of age and shows a normal 
psychomotor development. Except for hyperopia she 

















































Fig. 1 Metabolic control in dependence of OHCbl substitution. a Patient 1, b patient 2, c patient 3, and d patient 4. Concentrations of total 
homocystein (tHcy) in plasma [µmol/l] over the time are depicted by a rhombus. 1 mg OHCbl was injected IV (intravenous), IM (intramuscular) or 
SQ (subcutaneous), respectively, with varying frequency, demonstrated by the grey area (QW weekly, Q2W every 2 weeks, Q3W every 3 weeks, BIW 
twice a week, TIW three times a week, FIW five times a week, QD daily, E5D every 5 days)
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Patient 2
Patient 2, a girl, was born after 37 weeks of gestation by 
Caesarian section due to placenta praevia and intrauter-
ine growth retardation (birth weight 2240 g). She is the 
second child (G3P2) of healthy, non-consanguineous 
parents of Caucasian origin. She presented with respira-
tory distress after birth during the first hour of life. New-
born screening was unremarkable, but did not comprise 
remethylation disorders. A persistent ductus arteriosus 
Botalli required surgical occlusion at the age of 5 months. 
Patient 2 showed a severe failure to thrive, muscular 
hypotonia, developmental delay, and macrocytic anemia 
at 9 months of age. Diagnostic work-up revealed a mark-
edly elevated concentration of tHcy (180  µmol/l; refer-
ence range < 12) and low concentration of methionine 
(8 µmol/l; reference range 15–35). OHCbl (1 mg IV) was 
given, and the patient was transferred to our metabolic 
department for further work-up. At admission, the con-
centration of tHcy had dropped to 105  µmol/l. MMA 
in plasma was within the normal range (130  nmol/l; 
reference range 73–271). The pattern of acylcarnitines 
in plasma was unremarkable. Clinical work-up of the 
patient demonstrated epileptic encephalopathy, macu-
lar dystrophy of both eyes, and nystagmus. With clini-
cal and biochemical findings being highly indicative for 
a cobalamin-related remethylation disorder, intravenous 
treatment with OHCbl 1  mg IV per day was continued 
and oral treatment with betaine (250 mg/kg per day) and 
folic acid (10  mg per day) was added. With this treat-
ment, the concentration of tHcy dropped to 53  µmol/l 
(Fig.  1b). Sequence analysis revealed two compound 
heterozygous variants (c.904 + 469 T > C and c.923A > C, 
p.(Gln308Pro)) in the MTRR gene leading to the diagno-
sis of cblE disease. The variant c.904 + 469 T > C in intron 
6 is the most common disease-causing variant [15, 16]. 
The variant c.923A > C which is absent from the refer-
ence population database gnomAD [17] has not been 
described as disease-causing so far. In silico analyses pre-
dict a deleterious effect on the gene or gene product [18, 
19]. In accordance to the ACMG criteria, the variant was 
classified as variant of uncertain significance (VUS) [13].
With regard to long-term treatment, the parents were 
very reluctant to tolerate routine IM injections of OHCbl 
in their child. To avoid the burden of frequent IM injec-
tions, SQ administration of 1  mg OHCbl was initiated 
using a subcutaneous catheter device together with a 
portable infusion pump. The placement of the catheter 
and application of OHCbl infusions are readily accom-
plished by the parents at home and well tolerated by the 
patient. No adverse events occurred. The concentrations 
of tHcy remained stable with infusion intervals up to 
3 days (Fig. 1b). Weekly intervals resulted in an increase 
of tHcy concentration in plasma above 60 µmol/l.
Patient 2 is now 3 years old. An evaluation at 34 months 
of age revealed a global developmental delay with a devel-
opmental age of 12  months. Furthermore, she suffers 
from ataxia and a severe feeding disorder. She receives 
intensive physiotherapy, occupational and speech ther-
apy. The blood smear shows no evidence of macrocytic 
anemia.
Patient 3
Patient 3, a girl, is the first child of healthy, consanguin-
eous parents. She was born at term in Turkey. During 
the first months of life, developmental delay and micro-
cephaly were recognized. She was presented to our 
department at the age of 8 months. At presentation, con-
centration of tHcy was markedly elevated (164  µmol/l; 
reference range < 12). Mutation analysis revealed a 
homozygous pathogenic variant in the MMACHC gene 
(c.394C > T, p. Arg132Ter), confirming the diagnosis of 
cblC deficiency. The patient is now 16 years old. She suf-
fers from severe mental retardation, multifocal epilepsy, 
hyperkinetic movement disorder, astigmatism, hypero-
pia, strabismus, and QTc elongation.
Since diagnosis, she has been treated with OHCbl, folic 
acid (7.5  mg per day), and betaine (up to 6  g per day). 
During childhood, concentrations of tHcy in plasma 
were largely stable (mean 58  µmol/l) under treatment 
with OHCbl 1  mg IM every other week given by the 
local pediatrician. However, starting at 12  years of age, 
tHcy concentrations in plasma increased up to 92 µmol/l 
(Fig.  1c), and treatment was adjusted gradually. Weekly 
administration of OHCbl 1 mg IM still resulted in tHcy 
concentrations above the target range (< 60  µmol/l) [2]. 
As the patient did not tolerate IM injections at a higher 
frequency or higher injection volumes, the administra-
tion was changed to SQ. OHCbl was administered via a 
SQ catheter and a portable infusion pump at home by 
the parents. The pump-guided SQ administration was 
well tolerated. No complications occurred. Substitution 
of OHCbl 1  mg SQ three times a week finally resulted 
in plasma tHcy concentrations within the target range 
(Fig. 1c).
Patient 4
Patient 4, a boy, was born at term (birth weight 3610 g). 
He is the second child (G2P2) of healthy, non-consan-
guineous parents of Caucasian origin. Postnatal adapta-
tion was uneventful. Newborn screening was collected 
at 3 days of age and was unremarkable, but did not com-
prise remethylation disorders. At 3  months of age, the 
patient was admitted to hospital due to progressive mus-
cular hypotonia and drowsiness. He presented as floppy 
infant with little motor activity. Laboratory investigations 
showed neutropenia and megaloblastic anemia requiring 
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transfusion. Electroencephalography revealed encepha-
lopathy. Magnetic resonance imaging showed dilated 
lateral ventricles, hypoplasia of the corpus callosum, cer-
ebellar hypoplasia, and a small bridging vein thrombosis. 
Subsequent metabolic workup demonstrated a markedly 
elevated concentration of tHcy (179  µmol/l; reference 
range < 12) and a decreased concentration of methionine 
(2 µmol/l; reference range 9–42) in plasma with normal 
concentrations of propionylcarnitine and MMA. These 
findings are highly indicative for a cobalamin-related 
remethylation disorder, thus OHCbl 1 mg IM, folic acid 
20 mg PO, betaine 200 mg/kg PO, and methionine 50 mg 
PO per day were started. With this treatment, tHcy in 
plasma declined to 42  µmol/l (Fig.  1d) and methionine 
normalized. The diagnosis of cblG deficiency was con-
firmed by sequence analysis of the MTR gene. Two vari-
ants, the pathogenic variant c.3395G > A, p.Arg1132Gln 
[20] and the variant c.250-1G > C, p.? were identified in 
compound heterozygous state. The variant c.250-1G > C 
has not been described before (HGMD 2020.4) but was 
classified as (likely) pathogenic. It affects the canoni-
cal splice acceptor site of exon 3 resulting in either a 
frameshift with premature translational arrest, or exon 
skipping.
Within the following weeks, treatment was adjusted 
based on tHcy concentrations in plasma (Fig.  1d). 
To achieve tHcy concentrations as low as possible 
(< 40 µmol/l), 1 mg OHCbl every 3 weeks was sufficient. 
However, at the age of 31  months, these IM injections 
became a massive burden for the patient. He vigorously 
struggled against each injection. Both the parents and 
the home care nurse considered IM injections not to be 
acceptable any longer. Based on our previous experiences, 
we started SQ administration of OHCbl using an infusion 
pump. Patient 4 tolerated the placement of the SQ cathe-
ter and the infusion very well. Both could be executed by 
the parents during everyday life. Treatment was started 
with OHCbl 1  mg one time a week resulting in tHcy 
concentrations within the target range (< 60  µmol/l [2]) 
(Fig. 1d). An increase in administrations did not result in 
a further decrease of tHcy concentrations.
The patient is now 4  years of age. He has been diag-
nosed with a neurodevelopmental and developmental 
coordination disorder and requires occupational and 
physical therapy. At the age of 6  months he developed 
hydrocephalus communicans and a ventriculoperito-
neal shunt had to be placed. His blood count normalized 
within days and stayed normal.
Discussion
The treatment of cobalamin-related remethylation dis-
orders requires the lifelong parenteral administration of 
OHCbl. To date, this is mainly achieved by routine IM 
injections. The dosage and frequency of OHCbl adminis-
tration are titrated in each individual patient to the min-
imum effective dose in order to account for the painful 
injections. This may result in undertreatment, a possible 
risk factor for disease progression and the occurrence of 
complications [21].
We describe the parenteral administration of OHCbl 
using a SQ catheter system and a portable infusion pump 
in two patients with cblC, one patient with cblG, and one 
patient with cblE defect. To our knowledge, this is the 
first report of a pump-controlled SQ OHCbl infusion 
in patients with combined and isolated remethylation 
disorders.
All our patients required IM administrations of OHCbl 
that were not or no longer accepted by the patients and/or 
their parents regarding frequency or way of administra-
tion at some point of the disease course. The placement 
of a SQ catheter is an easy, almost painless procedure, 
which requires minimal medical skills. It was well toler-
ated by the patients and could readily be accomplished by 
the parents at home. In contrast, IM injections executed 
by the parents were not conceivable at any point. Once 
placed, the catheter device could be used for up to 3 days 
[22]. We did not encounter any adverse events such as 
infections of the catheter site or local infusion reactions. 
The slow SQ administration of OHCbl using an infusion 
pump prevented the pain induced by the swift delivery 
of the medication in IM or SQ injections. The use of a 
portable syringe driver pump of small dimensions and 
low weight allowed for a most flexible administration of 
OHCbl in everyday life e.g. during sleep, kindergarten, or 
school. All these aspects allowed for an individual OHCbl 
dosing at the required frequency and thus improving 
metabolic control in terms of tHcy concentrations within 
the target range or even continuing therapy [2].
The efficacy of SQ OHCbl administration in remeth-
ylation disorders is still under debate. In general, medica-
tions administered SQ have been found to be equivalent 
in efficiency when compared to other routes such as IV 
or PO [12]. OHCbl in particular is an ideal medication 
for subcutaneous administration on the basis of water 
solubility, neutral pH, and low viscosity [23]. A study on 
cblC patients found the biochemical effect of SQ admin-
istration to be identical to IM administration after more 
than 1 year of follow-up [9]. Another study suggested the 
SQ route to be less effective when compared to IM injec-
tions in an adult cblC patient [4].
Although the efficacy of a single SQ injection of OHCbl 
compared to a single IM injection of OHCbl may not be 
clear, the use of a SQ catheter enables more frequent dos-
ing without further punctures and thus might improve 
metabolic control. These assumptions are in line with 
reports on patients suffering from cblA methylmalonic 
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aciduria [11] and methylmalonic aciduria due to meth-
ylmalonyl-CoA mutase [10] who have been effectively 
treated using a SQ catheter for OHCbl injections.
As noted above, the pain and discomfort caused by 
both IM and SQ injections is not only related to the 
punctures, but also to the swiftly delivered volume of the 
medication, which is mostly 1  ml per 1  mg of OHCbl. 
As a consequence, IM and SQ administration of OHCbl 
is often limited to 1  mg. However, in addition to an 
increased frequency, a dose escalation might be effective 
to improve metabolic control in Cbl patients [9, 24–26]. 
The slow infusion of OHCbl using a pump allows for 
higher doses without discomfort or pain. As OHCbl has 
been shown to be stable in isotonic sodium chloride at 
room temperature up to 1 month [27], it may be admin-
istered at higher doses over several hours, if desired. 
Hence, this route of administration may provide a feasi-
ble possibility for treatment optimization studies [24].
The patients described in our report had an early onset 
disease phenotype or were diagnosed by newborn screen-
ing. In view of the fact that our approach is safe, effective, 
and acceptable for infants, toddlers, and severely affected 
patients, we also expect it to be a convenient alternative 
for juvenile and adult onset phenotypes.
Most of the knowledge about the management of 
remethylation disorders is derived from the experience 
with individuals with the cblC defect, the most frequent 
remethylation disorder [2]. In clinical practice, the rarer 
isolated as well as combined remethylation disorders 
are generally managed identically [2]. Thus, our experi-
ences derived from patients with cblC, cblG, and cblE 
may be translated to all cobalamin-related remethylation 
disorders.
Conclusions
In conclusion, pump-controlled infusion of OHCbl via 
a SQ catheter in cobalamin-related remethylation disor-
ders is safe, effective, and acceptable. The strength of the 
described SQ infusion therapy lies within the ease of use 
requiring minimal medical and technical skills and thus 
enabling parents to administer their children’s medica-
tion independently at home even in small neonates, chil-
dren, and severely impaired patients. It provides a large 
flexibility and minimal interference with daily life. The 
almost painless access and way of administration allevi-




We report the data of four patients with cobalamin-
related remethylation disorders (two patients with 
cblC (OMIM #277400), one patient with cblG (OMIM 
#250940), and one patient with cblE (OMIM #236270)) 
followed at our metabolic center. Data of the patients are 
reported anonymized. The study is in accordance with 
the guidelines of the local ethics committee. Written 
informed consent for publication of clinical details was 
obtained from the patients’ parents.
Biomarker analyses
Filter paper samples from newborn screening were ana-
lyzed by MS/MS as previously described [28–32]. For 
analysis of acylcarnitines in plasma, blood samples were 
collected in tubes prepared with lithium-heparin. Plasma 
was separated by centrifugation within 1  h after sam-
pling. Analysis was performed using electrospray ion-
ization-tandem mass spectrometry (ESI–MS/MS) [28, 
33, 34]. Organic acids were analyzed in urine using capil-
lary gas chromatography followed by mass spectrometry 
as described elsewhere [35]. Vitamin B12 was measured 
using a Cobas electrochemiluminescence immunoassay 
(ECLIA), homocysteine using an enzymatic assay (Roche 
Diagnostics, Mannheim) following the manufacturer’s 
instructions. Reference values are given according to the 
laboratories’ and manufacturers’ experience, respectively. 
MMA in plasma and urine were determined using gas 
chromatography (GC)-MS [36, 37].
Molecular analyses
Molecular analysis of the MMACHC (GenBank: 
NM_015506.3), MTRR (GenBank: NM_002454.2), and 
MTR gene (GenBank: NM_000254.2) was performed by 
Sanger sequencing [14, 32, 38].
Administration of vitamin B12 by subcutaneous infusion
1  mg of OHCbl, diluted in 2  ml isotonic saline solu-
tion, was administered via the Cleo® (teflon cannula, 
27 gauge/6  mm) 90 6/60 SQ infusion catheter system 
(Smiths medical, Grasbrunn) or Soft Glide® (steel can-
nula, 27 gauge/6 mm) SQ catheter set (THM, Duisburg). 
For controlled infusion over 1  h the portable CRONO 
S-PID infusion pump (LICHER MT GmbH, Wedemark) 
was used. The SQ catheters were changed according to 
the manufacturer’s recommendations every 2–3  days. 
Parents were educated to place the catheter and use the 
infusion pump independently at home.
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